期刊文献+

中医药辅助治疗哮喘合并过敏性鼻炎的疗效观察 被引量:14

Efficacy Observation of TCM in the Adjuvant Treatment of Asthma and Allergic Rhinitis
下载PDF
导出
摘要 目的:观察中医药辅助治疗哮喘合并过敏性鼻炎的临床疗效及并发症。方法:160例哮喘合并过敏性鼻炎的患者按就诊顺序单双号分成对照组和观察组,各80例。对照组患者行基本西医诊治,如采用氯雷他定和布地奈德治疗过敏性鼻炎,采用沙美特罗替卡松和孟鲁司特钠治疗哮喘等;观察组患者在对照组治疗基础上辅以中医药治疗(内治法+外治法)。两组疗程均为3个月。比较两组患者的临床疗效和并发症发生情况。结果:观察组、对照组分别有2、3例脱落病例。观察组患者的总有效率为97.43%,明显高于对照组的74.03%,两组比较差异有统计学意义(P<0.05)。观察组患者的并发症发生率为8.97%,明显低于对照组的19.48%,两组比较差异有统计学意义(P<0.05)。结论:中医药辅助治疗哮喘合并过敏性鼻炎,可明显减轻患者的临床症状,提高疗效,并减少并发症发生几率。 OBJECTIVE:To observe the clinical efficacy and complications of TCM in the adjuvant treatment of asthma and allergic rhinitis. METHODS:160 patients with asthma and allergic rhinitis were divided into control group and observation group according to the visiting order of odd or even,80 cases in each group. Control group received basic western medicine,such as loratadine and budesonide used for allergic rhinitis,salmeterol/fluticasone and leukotriene for asthma;observation group additionally received TCM(inline treatment + external treatment),the treatment course was 3 months. Clinical efficacy and complications in 2groups were compared. RESULTS:The observation group had 2 cases of fall-off patients,and the control group had 3 cases. The total effective rate in observation group was 97.43%,which was higher than control group(74.03%),the difference was statistically significant(P〈0.05). The incidence of complications in observation group was 8.97%,which was lower than control group(19.48%),the difference was statistically significant(P〈0.05). CONCLUSIONS:TCM can obviously relieve clinical symptoms,improve efficacy and reduce the incidence of complications in the adjuvant treatment of patients with asthma and allergic rhinitis.
出处 《中国药房》 CAS 北大核心 2016年第23期3255-3256,共2页 China Pharmacy
关键词 哮喘 过敏性鼻炎 中医药 辅助治疗 Asthma Allergic rhinitis Traditional Chinese medicine Adjuvant treatment
  • 相关文献

参考文献13

二级参考文献138

共引文献159

同被引文献149

引证文献14

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部